Yahoo Finance

TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique ...

TransCode expands its microRNA-based pipeline with Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma Philippe Calais, PharmD, PhD, ...
Yahoo Finance

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

BOSTON, May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA ...
FierceBiotech

TransCode rewrites future, securing $25M lifeline and phase 3 cancer vaccine

TransCode Therapeutics named Philippe Calais, Ph.D., as its CEO in a statement to disclose a pair of deals. (Feodora Chiosea/Getty Images) In a pair of deals, TransCode Therapeutics has bagged ...
Benzinga.com

Why TransCode Therapeutics (RNAZ) Stock Is Getting Hammered

TransCode Therapeutics shares are trading lower by 40.6% during Monday's session. The company disclosed plans for a potential reverse stock split in an open letter to its shareholders. Up Next: Get 5 ...